New Tests
Catch Up with New and Enhanced Tests in All Methodologies
Innovation is one of NeoGenomics’ company values. We mean that literally – innovation is one of our Core Values – and we take it personally. In 2016, we launched 50 new or enhanced tests. In 2017, we continue to innovative by launching new tests in hereditary and somatic molecular genetics, IHC, FISH, flow cytometry, and cytogenetics to keep our test menu at the forefront of cancer diagnostics. To stay up-to-date with our latest news, please sign up for our newsletter here.
Please Review Our List of Recently Launched Tests:
- B-ALL MRD Flow Panel (new 7-30-18)
- BCL10 IHC (new 7-23-18)
- PD-L1, 22C3 FDA (KEYTRUDA®) for Cervical (new 6-18-18)
- Sezary T-Cell Add-On Flow Panel (new 6-18-18)
- CDKN2A (p16) Deletion FISH for ALL (new 3-8-18)
- PPM1D Mutation Analysis (new 1-25-18)
- CDK2NA (p16) Deletion for Mesothelioma (new 10-10-17)
- PD-L1, 22C3 FDA (KEYTRUDA®) IHC for Gastric/GEA (new 9-29-17)
- NeoTYPE® GI Predictive Profile (new 7-17-17)
- ATRX IHC (new 6-12-17)
- MAL IHC (new 6-12-17)
- NeoTYPE® Discovery Profile (modified 6-4-17)
- NeoTYPE® Gastric Profile (modified 6-4-17)
- NeoTYPE® Esophageal Profile (modified 6-4-17)
- NeoTYPE® Ovarian Profile (modified 6-4-17)
- Tumor Mutation Burden (new 6-2-17)
- PD-L1, SP263 FDA (IMFINZI™) IHC (new 6-1-17)
- TOPO1 IHC (new 5-11-17)
- RRM1 IHC (new 5-11-17)
- Universal Fusion/Expression Profile (new 3-29-17)